Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07260825 · ClinicalTrials.gov registry record · Phase 2
Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial
A Phase 2 study, sponsored by TriHealth.
- Not yet
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT07260825 is a Phase 2 study that has not yet begun recruiting, run by TriHealth. The registered enrollment target is 44 participants.
The verdict
NCT07260825, a Phase 2 study, has not yet begun recruiting, sponsored by TriHealth.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
We are looking to see if patients using both topical testosterone and estrogen will have a greater improvement in pain with vaginal penetration compared to those using topical estrogen alone.
Interventions
- DRUG Estradiol 0.01% Vag Cream
- DRUG testosterone 0.1% and estradiol 0.01% vaginal cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-12 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07260825
The ClinicalTrials.gov registry entry for NCT07260825 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Estradiol 0.01% Vag Cream is the first listed.
NCT07260825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07260825 about?
NCT07260825 is a clinical study titled "Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial". We are looking to see if patients using both topical testosterone and estrogen will have a greater improvement in pain with vaginal penetration compared to those using topical estrogen alone.
What is the current status of trial NCT07260825?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-12. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07260825?
The interventions under investigation include: Estradiol 0.01% Vag Cream (DRUG), testosterone 0.1% and estradiol 0.01% vaginal cream (DRUG).
Who is sponsoring clinical trial NCT07260825?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.